Pregnancy RelatedNCT05849649
Mobile Application-based Exercise Intervention for Pregnant Women
A study testing BumptUp and Educational Brochure in people with Pregnancy Related and Postpartum, run by Western Kentucky University at 1 site in United States.
Trial summary
The overarching goal of this randomized controlled clinical trial is to test the efficacy of the mHealth app (BumptUp) for improving physical activity levels among pregnant and postpartum women in a rural setting. Read more about this study
- Who is it for?
- Ages 18 to 44 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pregnancy Related, Postpartum
- What is being tested?
- BumptUp and Educational Brochure
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 176 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2023to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 44 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-44
- Confirmed singleton viable pregnancy
- English-Speaking (the app is currently only available in English)
- Physician release to participate in exercise prior to study participation
- Ownership of a smartphone
- Patient at either Graves Gilbert Clinic or Women's Health Specialists
- Plans to deliver at The Medical Center in Bowling Green, KY.
Who cannot join
- Multiple gestation pregnancy
- Inability to provide voluntary informed consent
- Any medical condition (pregnancy-related or not) that would preclude exercise.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Rachel Tinius
Bowling Green, Kentucky, 42101
Rachel Tinius, PhD, 2707455026, rachel.tinius@wku.edu
About this study
Official title: Increasing Physical Activity Through a Mobile Health Intervention Among Pregnant and Postpartum Women in a Rural Setting
The overarching goal of this randomized controlled clinical trial is to test the efficacy of the mHealth app (BumptUp) for improving physical activity levels among pregnant and postpartum women in a rural setting. Secondary outcomes include weight status, dietary intake, glucose tolerance, blood pressure, and mental health.
Specific Aim 1. Conduct an RCT (N=176) to assess the efficacy of the mHealth intervention for increasing physical activity levels during pregnancy (13-15, 23-25, and 35-37 weeks gestation) and postpartum (6 and 12 weeks) among women in a rural setting.
Read more
Research Activities: The efficacy of BumptUp® will be determined by measuring physical activity levels (via accelerometry and surveys) between women who use the mobile app (intervention) and women who use only an educational brochure (attention control).
Specific Aim 2: Assess the efficacy of the mHealth intervention on important obstetric outcomes including maternal weight status, dietary intake, glucose tolerance, blood pressure, and mental health.
Research Activities: Maternal weight status, glucose tolerance, and blood pressure values will be obtained from patient charts. Dietary intake will be assessed via the National Cancer Institute Multifactor Screener. Maternal mental health status will be measured via The Edinberg Postpartum Depression Questionnaire, Center for Epidemiological Studies Depression Scale, and the State-Trait Anxiety Inventory.
Read the detailed description
A mobile application (app) that can increase physical activity during and after pregnancy is novel, timely, and critically important to maternal health. Mobile phone-based interventions show significant promise because they can be tailored to the target population, can be delivered at any place and at any time (with or without internet connection), are interactive, and are accessible to the majority of the population irrespective of socioeconomic status (96% of U.S. women ages 18-49 own smartphones). The use of mHealth apps has been associated with behavior change, specifically adaptation of healthy lifestyle approaches. The majority of pregnant women report using an app related to pregnancy; it is the health condition with the highest number of apps available. However, high-quality evidence-based mobile apps that address physical activity specifically for pregnancy do not exist. The overarching goal of this randomized controlled clinical trial is to test the efficacy of the mHealth app for improving physical activity levels among pregnant and postpartum women in a rural setting. Secondary outcomes include weight status, dietary intake, glucose tolerance, blood pressure, and mental health.
After contact is established and eligibility confirmed, participants (N=176) will undergo a screener, a baseline assessment, and then randomized to the mHealth intervention or the attention control group. All participants will have data collected at the following timepoints: baseline (13-15 weeks pregnant), mid-pregnancy (23-25 weeks), late pregnancy (35-37 weeks), and postpartum (6 and 12 weeks). [Of note, 12-week interventions during pregnancy are customary and have been shown to elicit clinically meaningful changes in outcomes. The pilot study protocol was 12 weeks of pregnancy and 12 weeks postpartum.] The proposed RCT will add an additional timepoint in early pregnancy (13-15 weeks), which will increase the length of the intervention to 39+ weeks. This will further enhance the likelihood of the intervention influencing behavior and outcomes.
There will also be three check-ins via telephone (two during pregnancy and one during postpartum upon medical clearance at ~6 weeks) to aid with retention, as well as allow participants to ask any questions about the app (intervention) or the educational brochure (attention control). The 13-15 week gestation time point was chosen because most women have had an initial prenatal appointment (to ensure viability) and the risk of miscarriage substantially reduced. The late pregnancy timepoint was selected as women tend to become the least active during late pregnancy. Six weeks postpartum was selected as this is when most women have their only postpartum clinical appointment (i.e. opportunity for objective clinical data extraction). The 12-week time point is important for assessing behavior as women transition back into activity after medical clearance, which is important for long-term sustained activity.
After the baseline assessment (13-15 weeks gestation), the women will be randomized to the intervention or attention control group. The intervention group will receive free access to the mobile app (BumptUp®). BumptUp® users will watch an introductory video on the app's features which reiterates the goal of the app: to reach the recommended 150 minutes per week of physical activity. The app contains evidence-based workout information and education as well as several resources aimed at increasing physical activity and overcoming barriers for women during and after pregnancy. Each app feature is not only developed as the result of feedback from rural study participants, but is developed with a specific mechanism for behavior change in mind.
The attention control group will undergo the exact same study protocol (parallel) and receive the same amount of interaction from the study team; however, participants will obtain an electronic evidence-based educational brochure about physical activity and dietary intake during pregnancy instead of access to BumptUp®. To ensure the control group is a true attention control, the study team has paid careful attention to recommendations and will ensure that the control group receives the exact same amount of interpersonal interaction as intervention participants (same number of emails, phone calls, surveys, and face-to-face interactions). Instead of a tutorial on the app at the time of randomization, participants will have an educational session with the study team about the educational brochure.
Data Collected at each timepoint: To assess the primary outcome of physical activity (Aim 1), participants will wear an Actigraph wGT3X-BT Accelerometer (ActiGraph LLC,) on their wrist for seven consecutive days at each time point (Pregnancy: 13-15 weeks, 23-25 weeks, 35-37 weeks, Postpartum: 6 and 12 weeks). Monitoring physical activity for one week at multiple time points is standard in exercise research. Actigraph provides an accurate and reliable way to assess overall physical activity levels. Wrist-worn tri-axel accelerometers are a valid measure of physical activity in pregnant women. Data will be collected for seven consecutive days at 30Hz. The accelerometer output will be sampled by a 12-bit analog-to-digital converter. Categories of activity will be determined using the following cut points: Sedentary (0-99counts/minute), light (100-1951 counts/min), moderate (1952-5724 counts/minute), and vigorous (≥5725 counts/min). The percentage of time spent sedentary as well as the amount of time spent participating in different categories of physical activity ranging from light to vigorous will be calculated. Non-wear times will be excluded from the analyses. Women will be asked to wear the devices for seven consecutive days without removal. If removed, it must be documented it so the study team can be sure it does not interfere with the analyses. The study team has a successful history of compliance with these devices among pregnant women, including the pilot study for the present intervention. Devices will be dropped off with careful instructions for when/how to wear the device and when/how to remove it. Because many women in the study reside in rural areas, the accelerometer can be delivered by mail with a prepaid return envelope to increase compliance. Because all participants will receive prenatal care at one of two clinics, prenatal appointments will also be utilized to meet participants and deliver/pick up accelerometer devices. Physical activity will also be assessed subjectively using the Exercise Vital Sign survey-a survey specifically designed to determine whether someone meets 150 minutes of physical activity per week (i.e. meets the recommendations from the ACOG).
The same participants and study design will be followed for Aim 2. The outcomes of focus for this aim will be obstetric outcomes with clear links to maternal morbidity and mortality rates, including maternal weight status, glucose tolerance, blood pressure, and mental health.
Medical data will be collected directly from patient charts in order to assess will be used to determine weight status, glucose tolerance, and blood pressure. Team members (Dr. Maire Blankenship and Dr. Leigh Lindsey) will pull data directly from the Graves Gilbert Clinic and Women's Health Specialist's electronic medical record systems. These data include height, weight, and blood pressure results at prenatal appointments that correspond to data collection time points (i.e., 12-17 weeks, 23-27 weeks (wider time ranges due to appointments still being monthly for many women during early-to-mid pregnancy), 35-37 weeks, and 6-weeks postpartum. All data at 12 weeks postpartum will be patient/participant self-report as there are no routine postpartum visits at 12 weeks. Per standard-of-care clinical protocols, oral glucose tolerance testing occurs at 24-28 weeks gestation and will be used to determine glucose tolerance. Extracted data will be used to determine the impact of the intervention on weight gain/retention, blood pressure, and glucose tolerance. The study team has already been granted permission to collect these data (see letters of support) and has a history of success at collecting these assessments per the pilot project.
To assess mental health, electronic surveys will be distributed at each time point. These include the Edinberg Postpartum Depression Questionnaire and the State-Trait Anxiety Inventory. Maternal depression and anxiety play a significant role in maternal morbidity and mortality, and physical activity improves symptoms of both during and after pregnancy. Therefore, it is important to understand if the mHealth app improves mental health. Research clearly shows a need to assess both anxiety and depression during and after pregnancy, as anxiety tends to be more common and more often overlooked. Therefore, the State-Trait Anxiety Inventory was chosen to measure anxiety. Further, it is exceedingly clear that exercise can assist with reducing anxiety. In order to assess the app's ability to improve dietary intakes, as well as account the possible confounding impact of dietary intake on weight status, the National Cancer Institute Multifactor (Diet) Screener will be provided as part of the electronic survey package.
At each time point, surveys will be administered via Research Electronic Data Capture (REDCap). During the pilot, data were successfully collected, and exit interviews indicate an acceptable level of participant burden.
- Conditions
- Pregnancy Related, Postpartum
- Being tested
- BumptUp, Educational Brochure
- Keywords
- exercise, mHealth, pregnancy, postpartum, rural
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BumptUpBehavioural
The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
Educational BrochureBehavioural
An evidence-based brochure on physical activity
| Study group | Role | What they receive |
|---|---|---|
| BumptUp Mobile App | Experimental | The intervention group will have full access to the BumptUp mobile app which includes exercise and dietary progress tracking, social support, evidence-based and safe exercise programming, videos, and symptom tracking. Receives: Behavioral: BumptUp |
| Educational Brochure/ Attention Control | Active comparator | This group will receive evidence-based exercise education the form a one-time brochure. Receives: Behavioral: Educational Brochure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Physical activity level (objective)
Measured via Actigraph accelerators
Measured: 13-15 weeks gestation
Physical activity level (objective)
Measured via Actigraph accelerometer
Measured: 23-25 weeks gestation
Physical activity level (objective)
Measured via Actigraph accelerometer
Measured: 35-37 weeks gestation
Physical activity level (subjective)
Measured via Exercise Vital Signs (survey)
Measured: 6 weeks postpartum
Physical activity level (objective)
Measured via Actigraph accelerometer
Measured: 12 weeks postpartum
Physical activity level (subjective)
Exercise Vital Sign Survey
Measured: 13-15 weeks gestation
Physical activity level (subjective)
Exercise Vital Sign Survey
Measured: 23-25 weeks gestation
Physical activity level (subjective)
Exercise Vital Sign Survey
Measured: 35-37 weeks gestation
Physical activity level (subjective)
Exercise Vital Sign Survey
Measured: 12 weeks postpartum
Secondary outcomes (27)
Maternal Weight Status
Measured via objective medical chart data on maternal weight
Measured: 13-15 weeks gestation
Maternal Weight Status
Measured via objective medical chart data on maternal weight
Measured: 23- 25 weeks gestation
Maternal Weight Status
Measured via objective medical chart data on maternal weight
Measured: 35-37 weeks gestation
Maternal Weight Status
Measured via objective medical chart data on maternal weight
Measured: 6 weeks postpartum
Maternal Weight Status
Self-reported weight data
Measured: 12 weeks postpartum
Dietary Intake
The National Cancer Institute Multifactor Screener
Measured: 13-15 weeks gestation
Dietary Intake
The National Cancer Institute Multifactor Screener
Measured: 23-25 weeks gestation
Dietary Intake
The National Cancer Institute Multifactor Screener
Measured: 35-37 weeks gestation
Dietary Intake
The National Cancer Institute Multifactor Screener
Measured: 6 weeks postpartum
Dietary Intake
The National Cancer Institute Multifactor Screener
Measured: 12 weeks postpartum
Glucose Tolerance
Oral Glucose Tolerance test results obtained from routine clinical assessments and extracted from charts
Measured: 24-28 weeks gestation
Blood Pressure (systolic and diastolic)
Extracted from clinical charts
Measured: 13-15 weeks gestation
Blood Pressure (systolic and diastolic)
Extracted from clinical charts
Measured: 23-25 weeks gestation
Blood Pressure (systolic and diastolic)
Extracted from clinical charts
Measured: 35-37 weeks gestation
Blood Pressure (systolic and diastolic)
Extracted from clinical charts
Measured: 6 weeks postpartum
Mental Health (Depression)
The Edinberg Postpartum Depression Questionnaire (Minimum value:0, maximum value 30). Higher scores indicate a worse outcome/more likely to be depressed. Anything over 12 is considered to have depression.
Measured: 13-15 weeks gestation
Mental Health (Depression)
The Edinberg Postpartum Depression Questionnaire (Minimum value:0, maximum value 30). Higher scores indicate a worse outcome/more likely to be depressed. Anything over 12 is considered to have depression.
Measured: 23-35 weeks gestation
Mental Health (Depression)
The Edinberg Postpartum Depression Questionnaire (Minimum value:0, maximum value 30). Higher scores indicate a worse outcome/more likely to be depressed. Anything over 12 is considered to have depression.
Measured: 35-37 weeks gestation
Mental Health (Depression)
The Edinberg Postpartum Depression Questionnaire (Minimum value:0, maximum value 30). Higher scores indicate a worse outcome/more likely to be depressed. Anything over 12 is considered to have depression.
Measured: 6 weeks postpartum
Mental Health (Depression)
The Edinberg Postpartum Depression Questionnaire (Minimum value:0, maximum value 30). Higher scores indicate a worse outcome/more likely to be depressed. Anything over 12 is considered to have depression.
Measured: 12 weeks postpartum
Mental Health (Anxiety)
State-Trait Anxiety Inventory
Measured: 13-15 weeks gestation
Mental Health (Anxiety)
State-Trait Anxiety Inventory. This is a 40-question survey using a 4-point Likert Scale ranging from almost never to almost always. Scores for both State Anxiety and Trait Anxiety (20 questions each) range from 20 to 80, with higher scores indicating higher levels of anxiety.
Measured: 23-25 weeks gestation
Mental Health (Anxiety)
State-Trait Anxiety Inventory This is a 40-question survey using a 4-point Likert Scale ranging from almost never to almost always. Scores for both State Anxiety and Trait Anxiety (20 questions each) range from 20 to 80, with higher scores indicating higher levels of anxiety.
Measured: 35-37 weeks gestation
Mental Health (Anxiety)
State-Trait Anxiety Inventory This is a 40-question survey using a 4-point Likert Scale ranging from almost never to almost always. Scores for both State Anxiety and Trait Anxiety (20 questions each) range from 20 to 80, with higher scores indicating higher levels of anxiety.
Measured: 6 weeks postpartum
Mental Health (Anxiety)
State-Trait Anxiety Inventory This is a 40-question survey using a 4-point Likert Scale ranging from almost never to almost always. Scores for both State Anxiety and Trait Anxiety (20 questions each) range from 20 to 80, with higher scores indicating higher levels of anxiety.
Measured: 12 weeks postpartum
Neonatal Body Composition
Air Displacement Plethysmography (Bod Pod)
Measured: 24-48 hours post-delivery
Neonatal body fat percentage
Skinfold Calipers (4 site method)
Measured: 24-48 hours post-delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2023
- Study start1 Aug 2023
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pregnancy RelatedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 176 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Western Kentucky University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rachel A Tinius, PhD, Principal investigator, Western Kentucky University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05849649
- Sponsor's protocol ID
- IRB 20-257
- Status last verified
- Feb 2026
- First submitted
- 29 Mar 2023
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Increasing Physical Activity Through a Mobile Health Intervention Among Pregnant and Postpartum Women in a Rural Setting
- ClinicalTrials.gov ID
- NCT05849649
- Acronym / sponsor ID
- IRB 20-257
- Conditions
- Pregnancy Related, Postpartum
- Keywords
- exercise, mHealth, pregnancy, postpartum, rural
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 176 participants (estimated)
- Lead sponsor
- Western Kentucky UniversityUniversity, hospital or other
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 9 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching goal of this randomized controlled clinical trial is to test the efficacy of the mHealth app (BumptUp) for improving physical activity levels among pregnant and postpartum women in a rural setting. Secondary outcomes include weight status, dietary intake, glucose tolerance, blood pressure, and mental health.
Specific Aim 1. Conduct an RCT (N=176) to assess the efficacy of the mHealth intervention for increasing physical activity levels during pregnancy (13-15, 23-25, and 35-37 weeks gestation) and postpartum (6 and 12 weeks) among women in a rural setting.
Research Activities: The efficacy of BumptUp® will be determined by measuring physical activity levels (via accelerometry and surveys) between women who use the mobile app (intervention) and women who use only an educational brochure (attention control).
Specific Aim 2: Assess the efficacy of the mHealth intervention on important obstetric outcomes including maternal weight status, dietary intake, glucose tolerance, blood pressure, and mental health.
Research Activities: Maternal weight status, glucose tolerance, and blood pressure values will be obtained from patient charts. Dietary intake will be assessed via the National Cancer Institute Multifactor Screener. Maternal mental health status will be measured via The Edinberg Postpartum Depression Questionnaire, Center for Epidemiological Studies Depression Scale, and the State-Trait Anxiety Inventory.
Detailed description
A mobile application (app) that can increase physical activity during and after pregnancy is novel, timely, and critically important to maternal health. Mobile phone-based interventions show significant promise because they can be tailored to the target population, can be delivered at any place and at any time (with or without internet connection), are interactive, and are accessible to the majority of the population irrespective of socioeconomic status (96% of U.S. women ages 18-49 own smartphones). The use of mHealth apps has been associated with behavior change, specifically adaptation of healthy lifestyle approaches. The majority of pregnant women report using an app related to pregnancy; it is the health condition with the highest number of apps available. However, high-quality evidence-based mobile apps that address physical activity specifically for pregnancy do not exist. The overarching goal of this randomized controlled clinical trial is to test the efficacy of the mHealth app for improving physical activity levels among pregnant and postpartum women in a rural setting. Secondary outcomes include weight status, dietary intake, glucose tolerance, blood pressure, and mental health.
After contact is established and eligibility confirmed, participants (N=176) will undergo a screener, a baseline assessment, and then randomized to the mHealth intervention or the attention control group. All participants will have data collected at the following timepoints: baseline (13-15 weeks pregnant), mid-pregnancy (23-25 weeks), late pregnancy (35-37 weeks), and postpartum (6 and 12 weeks). [Of note, 12-week interventions during pregnancy are customary and have been shown to elicit clinically meaningful changes in outcomes. The pilot study protocol was 12 weeks of pregnancy and 12 weeks postpartum.] The proposed RCT will add an additional timepoint in early pregnancy (13-15 weeks), which will increase the length of the intervention to 39+ weeks. This will further enhance the likelihood of the intervention influencing behavior and outcomes.
There will also be three check-ins via telephone (two during pregnancy and one during postpartum upon medical clearance at ~6 weeks) to aid with retention, as well as allow participants to ask any questions about the app (intervention) or the educational brochure (attention control). The 13-15 week gestation time point was chosen because most women have had an initial prenatal appointment (to ensure viability) and the risk of miscarriage substantially reduced. The late pregnancy timepoint was selected as women tend to become the least active during late pregnancy. Six weeks postpartum was selected as this is when most women have their only postpartum clinical appointment (i.e. opportunity for objective clinical data extraction). The 12-week time point is important for assessing behavior as women transition back into activity after medical clearance, which is important for long-term sustained activity.
After the baseline assessment (13-15 weeks gestation), the women will be randomized to the intervention or attention control group. The intervention group will receive free access to the mobile app (BumptUp®). BumptUp® users will watch an introductory video on the app's features which reiterates the goal of the app: to reach the recommended 150 minutes per week of physical activity. The app contains evidence-based workout information and education as well as several resources aimed at increasing physical activity and overcoming barriers for women during and after pregnancy. Each app feature is not only developed as the result of feedback from rural study participants, but is developed with a specific mechanism for behavior change in mind.
The attention control group will undergo the exact same study protocol (parallel) and receive the same amount of interaction from the study team; however, participants will obtain an electronic evidence-based educational brochure about physical activity and dietary intake during pregnancy instead of access to BumptUp®. To ensure the control group is a true attention control, the study team has paid careful attention to recommendations and will ensure that the control group receives the exact same amount of interpersonal interaction as intervention participants (same number of emails, phone calls, surveys, and face-to-face interactions). Instead of a tutorial on the app at the time of randomization, participants will have an educational session with the study team about the educational brochure.
Data Collected at each timepoint: To assess the primary outcome of physical activity (Aim 1), participants will wear an Actigraph wGT3X-BT Accelerometer (ActiGraph LLC,) on their wrist for seven consecutive days at each time point (Pregnancy: 13-15 weeks, 23-25 weeks, 35-37 weeks, Postpartum: 6 and 12 weeks). Monitoring physical activity for one week at multiple time points is standard in exercise research. Actigraph provides an accurate and reliable way to assess overall physical activity levels. Wrist-worn tri-axel accelerometers are a valid measure of physical activity in pregnant women. Data will be collected for seven consecutive days at 30Hz. The accelerometer output will be sampled by a 12-bit analog-to-digital converter. Categories of activity will be determined using the following cut points: Sedentary (0-99counts/minute), light (100-1951 counts/min), moderate (1952-5724 counts/minute), and vigorous (≥5725 counts/min). The percentage of time spent sedentary as well as the amount of time spent participating in different categories of physical activity ranging from light to vigorous will be calculated. Non-wear times will be excluded from the analyses. Women will be asked to wear the devices for seven consecutive days without removal. If removed, it must be documented it so the study team can be sure it does not interfere with the analyses. The study team has a successful history of compliance with these devices among pregnant women, including the pilot study for the present intervention. Devices will be dropped off with careful instructions for when/how to wear the device and when/how to remove it. Because many women in the study reside in rural areas, the accelerometer can be delivered by mail with a prepaid return envelope to increase compliance. Because all participants will receive prenatal care at one of two clinics, prenatal appointments will also be utilized to meet participants and deliver/pick up accelerometer devices. Physical activity will also be assessed subjectively using the Exercise Vital Sign survey-a survey specifically designed to determine whether someone meets 150 minutes of physical activity per week (i.e. meets the recommendations from the ACOG).
The same participants and study design will be followed for Aim 2. The outcomes of focus for this aim will be obstetric outcomes with clear links to maternal morbidity and mortality rates, including maternal weight status, glucose tolerance, blood pressure, and mental health.
Medical data will be collected directly from patient charts in order to assess will be used to determine weight status, glucose tolerance, and blood pressure. Team members (Dr. Maire Blankenship and Dr. Leigh Lindsey) will pull data directly from the Graves Gilbert Clinic and Women's Health Specialist's electronic medical record systems. These data include height, weight, and blood pressure results at prenatal appointments that correspond to data collection time points (i.e., 12-17 weeks, 23-27 weeks (wider time ranges due to appointments still being monthly for many women during early-to-mid pregnancy), 35-37 weeks, and 6-weeks postpartum. All data at 12 weeks postpartum will be patient/participant self-report as there are no routine postpartum visits at 12 weeks. Per standard-of-care clinical protocols, oral glucose tolerance testing occurs at 24-28 weeks gestation and will be used to determine glucose tolerance. Extracted data will be used to determine the impact of the intervention on weight gain/retention, blood pressure, and glucose tolerance. The study team has already been granted permission to collect these data (see letters of support) and has a history of success at collecting these assessments per the pilot project.
To assess mental health, electronic surveys will be distributed at each time point. These include the Edinberg Postpartum Depression Questionnaire and the State-Trait Anxiety Inventory. Maternal depression and anxiety play a significant role in maternal morbidity and mortality, and physical activity improves symptoms of both during and after pregnancy. Therefore, it is important to understand if the mHealth app improves mental health. Research clearly shows a need to assess both anxiety and depression during and after pregnancy, as anxiety tends to be more common and more often overlooked. Therefore, the State-Trait Anxiety Inventory was chosen to measure anxiety. Further, it is exceedingly clear that exercise can assist with reducing anxiety. In order to assess the app's ability to improve dietary intakes, as well as account the possible confounding impact of dietary intake on weight status, the National Cancer Institute Multifactor (Diet) Screener will be provided as part of the electronic survey package.
At each time point, surveys will be administered via Research Electronic Data Capture (REDCap). During the pilot, data were successfully collected, and exit interviews indicate an acceptable level of participant burden.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BumptUp Mobile App | Experimental | Behavioral: BumptUpThe intervention group will have full access to the BumptUp mobile app which includes exercise and dietary progress tracking, social support, evidence-based and safe exercise programming, videos, and symptom tracking. |
| Educational Brochure/ Attention Control | Active comparator | Behavioral: Educational BrochureThis group will receive evidence-based exercise education the form a one-time brochure. |
Who may qualify
- Ages
- 18 to 44 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Age 18-44
- Confirmed singleton viable pregnancy
- English-Speaking (the app is currently only available in English)
- Physician release to participate in exercise prior to study participation
- Ownership of a smartphone
Key exclusion criteria (3 listed)
- Multiple gestation pregnancy
- Inability to provide voluntary informed consent
- Any medical condition (pregnancy-related or not) that would preclude exercise.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BumptUpThe app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy. | Behavioural | BumptUp Mobile App |
| Educational BrochureAn evidence-based brochure on physical activity | Behavioural | Educational Brochure/ Attention Control |
Primary outcome
Physical activity level (objective)
Time frame: 13-15 weeks gestation
Measured via Actigraph accelerators
Physical activity level (objective)
Time frame: 23-25 weeks gestation
Measured via Actigraph accelerometer
Physical activity level (objective)
Time frame: 35-37 weeks gestation
Measured via Actigraph accelerometer
Physical activity level (subjective)
Time frame: 6 weeks postpartum
Measured via Exercise Vital Signs (survey)
Physical activity level (objective)
Time frame: 12 weeks postpartum
Measured via Actigraph accelerometer
Physical activity level (subjective)
Time frame: 13-15 weeks gestation
Exercise Vital Sign Survey
Physical activity level (subjective)
Time frame: 23-25 weeks gestation
Exercise Vital Sign Survey
Physical activity level (subjective)
Time frame: 35-37 weeks gestation
Exercise Vital Sign Survey
Physical activity level (subjective)
Time frame: 12 weeks postpartum
Exercise Vital Sign Survey
27 secondary outcomes
Maternal Weight Status
Time frame: 13-15 weeks gestation
Maternal Weight Status
Time frame: 23- 25 weeks gestation
Maternal Weight Status
Time frame: 35-37 weeks gestation
Maternal Weight Status
Time frame: 6 weeks postpartum
Maternal Weight Status
Time frame: 12 weeks postpartum
Dietary Intake
Time frame: 13-15 weeks gestation
Dietary Intake
Time frame: 23-25 weeks gestation
Dietary Intake
Time frame: 35-37 weeks gestation
Dietary Intake
Time frame: 6 weeks postpartum
Dietary Intake
Time frame: 12 weeks postpartum
Glucose Tolerance
Time frame: 24-28 weeks gestation
Blood Pressure (systolic and diastolic)
Time frame: 13-15 weeks gestation
Blood Pressure (systolic and diastolic)
Time frame: 23-25 weeks gestation
Blood Pressure (systolic and diastolic)
Time frame: 35-37 weeks gestation
Blood Pressure (systolic and diastolic)
Time frame: 6 weeks postpartum
Mental Health (Depression)
Time frame: 13-15 weeks gestation
Mental Health (Depression)
Time frame: 23-35 weeks gestation
Mental Health (Depression)
Time frame: 35-37 weeks gestation
Mental Health (Depression)
Time frame: 6 weeks postpartum
Mental Health (Depression)
Time frame: 12 weeks postpartum
Mental Health (Anxiety)
Time frame: 13-15 weeks gestation
Mental Health (Anxiety)
Time frame: 23-25 weeks gestation
Mental Health (Anxiety)
Time frame: 35-37 weeks gestation
Mental Health (Anxiety)
Time frame: 6 weeks postpartum
Mental Health (Anxiety)
Time frame: 12 weeks postpartum
Neonatal Body Composition
Time frame: 24-48 hours post-delivery
Neonatal body fat percentage
Time frame: 24-48 hours post-delivery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Pregnancy Related
RecruitingPhase 1/2
Dexamethasone for Ureteral STent Symptoms (DUSTS)
Ureteral Stent-Related Symptom
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Recruiting
Scaling up Maternal Health Equity Best Practices
Maternal Mortality Disparities, Maternal Morbidity Disparities
Active, not recruiting
Assessing the Use of Wearable Activity Trackers in a Pregnancy Cohort
Pregnancy Related
RecruitingObservational study
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rachel A Tinius, PhD principal investigator
Western Kentucky University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BumptUp and Educational Brochure in people with Pregnancy Related and Postpartum, run by Western Kentucky University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rachel A Tinius, PhD (2707455026, rachel.tinius@wku.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physical activity level (objective) (time frame: 13-15 weeks gestation). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.